Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects

ABCDEF 1 Hui Ma*
BCDEF 2 Wenping Zhang*
ABCDEF 2 Xiaoying Yang*
ABCDEF 2 Yuxin Zhang
ABC 2 Shijie Wei
BCF 2 Hao Zhang
BC 2 Yanni Ma
ABCD EFG 2 Hongwan Dang
* Hui Ma, Wenping Zhang and Xiaoying Yang have contributed equally to this work

Corresponding Author:
Hongwan Dang, e-mail: dhwbeining@163.com

Source of support:
This work was supported by the General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China

Background: Bupropion (BUP) is an antidepressant and its pharmacological activity is mediated by its major metabolite, hydroxybupropion (HBUP). We investigated the effects of genetic polymorphisms of CYP2B6 on BUP and HBUP to provide certain evidence on the clinical rational administration of BUP.

Material/Methods: Plasma BUP and HBUP concentrations were assayed using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).

Results: A total of 23 healthy volunteers (eleven participants with CYP2B6*1/*1, 7 participants with CYP2B6*1/*6, 3 participants with CYP2B6*4/*6, and 2 participants with CYP2B6*1/*4) received orally administered 150 mg of BUP according to protocol. Blood samples were obtained up to 96 hours after administration. The whole blood was subject to genotyping by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). The concentration-time curve (AUC\textsubscript{(0\textendash96)}), maximum plasma concentration (C\textsubscript{\text{max}}), and terminal half-life (t\textsubscript{1/2}) values of BUP in CYP2B6*1/*4 were lower than those of CYP2B6*1/*1. By contrast, the time to C\textsubscript{\text{max}} (t\textsubscript{\text{max}}) value of the former was higher than that of the latter. The HBUP AUC\textsubscript{(0\textendash96)} values in CYP2B6*4/*6 and CYP2B6*1/*4 increased to values 1.12-fold and 1.98-fold, compared with CYP2B6*1/*1 carriers. However, the HBUP C\textsubscript{\text{max}} values in CYP2B6*4/*6 and CYP2B6*1/*4 increased by 1.12-fold and 1.97-fold, whereas the HBUP C\textsubscript{\text{max}} value in CYP2B6*1/*6 decreased to a value 1.64-fold lower than that in CYP2B6*1/*1.

Conclusions: Genetic polymorphisms of CYP2B6 influence the pharmacokinetic parameters of BUP and HBUP and thus establish rational BUP administration for Chinese patients in clinical settings.

MeSH Keywords: Clinical Trial, Phase I • Pharmacokinetics • Polymorphism, Single Nucleotide

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/909227

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
Background

Depression is a major psychiatric disorder and may significantly lower the quality of life and increase the burden of distress [1,2]. Depressive symptoms have a prevalence rate of 20–64% among patients in hospitals and 15–45% among elderly people with medical problems [3,4]. At present, effective drugs that can cure depression remain unavailable.

Bupropion (BUP) is a smoking cessation and antidepressant drug and functions as an effective norepinephrine and dopamine uptake inhibitor. BUP is metabolized to 3 major metabolites, namely, hydroxybupropion (HBUP), threohydrobupropion (TBUP), and erythrohydrobupropion (EBUP) [5,6]. BUP is also used for treating Parkinson disease, and it is metabolized primarily by CYP2B6 [7]. However, the metabolic mechanisms of BUP are currently unclear. Meanwhile, HBUP is the primary active metabolite for smoking cessation and anti-depression in humans.

The CYP3A4 system metabolizes BUP into either TBUP or EBUP, albeit at limited quantities [8]. CYP2B6 is the most effective enzyme in the second subgroup of cytochrome P450, but its genes are prone to mutation [9]. The predominant haplotypes associated with BUP metabolism are allele*4, allele*6, and allele*9 in CYP2B6. The A785G variant exists in allele*4; the G516T variant occurs in allele*9; and allele*6 consists of A785G and G516T variants [10].

Induction or inhibition of CYP2B6 activity reflected by BUP hydroxylation were extensively investigated in previous studies [11,12]. Both in vivo and in vitro studies showed that allele*4 relates to increased catalytic activity and accelerates the transformation of BUP into HBUP [6]. Meanwhile, CYP2B6*4 variants raise the catalytic activity of CYP2B6 and increase the BUP clearance to greater extent than wild-type allele CYP2B6*1 [13]. The presence of homozygous and heterozygous CYP2B6*6 results in HBUP concentrations is lower than those observed in the presence of its wild-type allele [6,14]. Moreover, other studies establish a strong correlation between allele*6 variants and BUP clearance or plasma HBUP levels [10,14]. A similar extent of induction for BUP hydroxylation by metamizole occurs in CYP2B6*6 alleles [15]. Reduced CYP2B6 function is observed in the presence of CYP2B6*6, this reduction results in decreased HBUP concentration and higher elevated plasma BUP concentration in allele*6 variants compared with that in the wild-type allele [6]. At high G516T polymorphism frequencies, allele*9 exhibits low enzymatic function [16]. Meanwhile, CYP2B6 polymorphisms that influence BUP and HBUP metabolism and effects remains unknown.

In the present study, the effects of the genetic polymorphisms of CYP2B6 on the pharmacokinetics of BUP and HBUP among healthy Chinese participants was investigated to provide a strong evidence that supports the rationality of BUP administration to healthy Chinese patients.

Material and Methods

Ethic statement

Written informed consents were obtained from the volunteers. The study protocol was approved by the Ethics Committee of the General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.

Study participants

A total of 23 healthy Chinese participants from Ningxia enrolled in the Phase I clinical trial who were successfully genotyped with specific CYP2B6 genotypes (11 participants with CYP2B6*1/*1, 7 participants with CYP2B6*1/*6, 3 participants with CYP2B6*4/*6, and 2 participants with CYP2B6*1/*4) were enrolled in this study. Study participants were ascertained as healthy and without disease history during physical examinations. Participants also abstained from drugs, alcohol, caffeine-containing beverages, cigarettes, and nutritional supplements for 2 weeks before study commencement and throughout the study [17]. Participants were male, aged 18–28 years, weighed 60–80 kg, and had a normal body mass index range (19–24 kg/m²). Hongwan Dang and Xiaoying Yang together created the study group according to selection criteria.

Study design

The clinical protocol was designed in a 2-process, 2-phase, 2-sequence, randomized, and crossover manner over a 2-week washout period between phases [18,19]. After overnight fasting and on day 1, from 6:00 am to 8:00 am, the participants could not have any food or water, then 150 mg of BUP (a tablet of 150 mg of BUP SR; Disha, Shandong, or Jingxin, Zhejiang) was orally administered with 200 mL of water at 8:00 am. Each participant drank 200 mL of water at 10:00 am, ingested meals at 12:00 pm and at 18:00 pm and drank water freely after 12:00 pm. On day 15, the participants changed to administration of another tablet at concordant conditions. Participants had no other food except the standard meals given during the study.

Blood sampling

Serial blood samples (5 mL) were collected with a forearm indwelling venous catheter 1 hour prior to dosing and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, and 96 hours after BUP administration. Blood samples were stored in EDTA-K2 tubes, and centrifuged (3000 rpm, 5 min) within 0.5 hours. The
separated plasma samples and blood cells were immediately stored at -80°C until analysis.

Concentration assay

We added 10 μL of venlafaxine (400 ng/mL) to 100 μL of plasma and then mixed this with 300 μL methanol used to precipitate proteins. The mixture was vortexed for 5 min and centrifuged at 14 000 rpm for 10 min at 4°C. Then 200 μL of supernatant was transferred into the autosampler vial for analysis. Plasma BUP and HBUP concentrations were determined [20,21] with high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) [22,23] (LC-30A™, Shimadzu, Kyoto, Japan; API 4000™, Applied Biosystems, Framingham, MA, USA), equipped with a Shimpack XR-ODSIII column (1.6 µm, 50×2.0 mm, Japan) and programmed mobile phase conditions of (acetonitrile: 10 mM ammonium formate/B): A) at 0 min, 5% B; at 2.5 min, 30% B; at 3.0 min, 30% B; at 3.5 min, 5% B; at 4.0 min, Stop (v/v) at a flow rate of 0.3 mL/min. Venlafaxine was used as internal standard (IS). The subsequent modes of MRM ion transitions were m/z 240.1–184.2 for BUP, m/z 256.1–238.3 for HBUP, and m/z 278.1–260.5 for IS. The [M+H]+ ions were represented by these transitions.

Calculation of pharmacokinetic parameters

Maximum plasma concentration (C_{max}) and time to C_{max} (t_{max}) were obtained from the concentration-time data. The area under the concentration-time curve (AUC) showed the extent of BUP absorption or extent of HBUP to which the related CYP450 metabolized BUP. λ₁ is the elimination rate constant determined from the terminal slope of the concentration-time plot. The terminal half-life (t_{1/2}), which shows the time of half-drug elimination, was calculated as 0.693/λ₁. The parameters of AUC_{0→t_{max}} C_{max}, t_{max} and t_{1/2} were calculated through the noncompartmental method in DAS 3.0 software package (Bojia Corp., Shanghai, China). The concentration-time curve and table of 23 participants were calibrated and designed.

Genotyping of CYP2B6

The genomic DNA from blood cells was extracted using Blood DNA Kit (50) (e.g.N.A™, OMEGA, Norcross, GA, USA). CYP2B6*4 (A785G) and CYP2B6*6 (A785G, G516T) genotypes were ascertained after amplification by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The PCR conditions consisted of initial denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 secs, annealing at 60°C for 40 secs for A785G and 58°C for G516T, and extension at 72°C for 1 min. Then 50 μL of PCR production was transferred into 1.5 mL EP tube, which contained 200 ng of DNA, 10 μM of each primer pair, 2.5 μM of dNTPs, 19 μL of ddH₂O, and 25 μL of Taq DNA polymerase (Takara, Dalian, China) for amplification at given PCR conditions. The genotypes of A785G were confirmed by StyI (Thermo Scientific, EU) at 60°C overnight, and G516T were ascertained by BsrI (New England Biolabs, America) at 65°C for 15 min [24].

Genotype and diplotype

The diplotype of CYP2B6*1/*1 showed A785A and G516G. A785G and G516T were the diplotype of CYP2B6*1/*6. Genotype of CYP2B6*1/*6 consisted of G785G and G516T. A785G and G516G occurred in CYP2B6*1/*4 diplotype.

Statistical analysis

One-way ANOVA and Mann-Whitney U or Kruskal-Wallis tests were used to evaluate AUC_{0→t_{max}}, C_{max}, t_{max}, and t_{1/2} between different groups with 95% confidence intervals (CIs). Results were expressed as mean ± standard deviation (mean ±SD) in the table and figure. Statistical results were performed with SPSS (version 22.0, IBM, Armonk, NY, USA) for windows. P values below 0.05 were considered statistically significant.

Results

BUP and HBUP concentrations

The lower limits of the quantification for BUP and HBUP were 0.500 and 0.600 ng/mL and the assay ranges used were 0.500–400 ng/mL and 0.600–480 ng/mL, respectively. The mean correlation coefficients for BUP and HBUP were 0.9986 and 0.9961. The accuracy, intra-day and inter-day precision, measured by HPLC-MS/MS, were less than ±15.0%. Our method met the criteria of the Guidance for Industry Bioanalytical Method Validation (FDA) and Guideline on Bioanalytical Method Validation (EMA).

Classification of CYP2B6

CYP2B6 genotypes were categorized as 516 G>T and 785 A>G mutations. Participants were classified into 4 groups, namely, CYP2B6*1/*1 (n=11), CYP2B6*1/*6 (n=7), CYP2B6*4/*6 (n=3), and CYP2B6*1/*4 mutants (n=2).

Effects of CYP2B6 on pharmacokinetic parameters of BUP and HBUP

The relationships between pharmacokinetic properties of BUP and HBUP and genotypes of CYP2B6 are shown in Figure 1 and Table 1. The pharmacokinetic parameter results of BUP and HBUP depend on CYP2B6 genotypes-generated differences. The AUC_{0→t_{max}}, AUC_{0→∞}, and C_{max}, of HBUP were significantly different between CYP2B6*1/*1 and CYP2B6*1/*6 participants, CYP2B6*1/*4 and CYP2B6*1/*4 participants, CYP2B6*1/*6 and
CYP2B6*1/*1, CYP2B6*1/*4, CYP2B6*4/*6, and CYP2B6*1/*6 participants, or CYP2B6*4/*6 and CYP2B6*1/*4 participants (all P values were below 0.05). The pharmacokinetic parameters of BUP among the 4 groups did not reach statistical difference. AUC_{0→∞} of BUP in CYP2B6*1/*1 carriers was higher. Moreover, AUC_{0→∞} of HBUP in CYP2B6*4/*6 and CYP2B6*1/*4 carriers increased by 1.12-fold and 1.98-fold compared with CYP2B6*1/*1 carriers, respectively. Similarly, C_{max} of HBUP in CYP2B6*4/*6 and CYP2B6*1/*4 carriers increased 1.12-fold and 1.97-fold compared with CYP2B6*1/*1 carriers. Meanwhile, AUC_{0→∞} of HBUP in CYP2B6*1/*1 carriers was 1.51-fold higher than that in CYP2B6*1/*6 carriers. C_{max} of HBUP in CYP2B6*1/*6 carriers was decreased by 1.64-fold over CYP2B6*1/*1 carriers.

However, the difference between t_{max} and t_{1/2} of participants carrying CYP2B6*4/*6 genotypes was nonsignificant.

### Discussion

In this study, plasma concentrations of BUP and HBUP were determined by HPLC-MS/MS, and pharmacokinetic parameters were calculated by noncompartmental method using Phoenix WinNonlin 6.3 and DAS 3.0 software package. CYP2B6 variants and SNPs were identified through a combination of PCR and RFLP. We found that pharmacokinetic parameters of BUP and HBUP were greatly influenced by CYP2B6 genetic polymorphisms among healthy Chinese study participants.

#### Table 1. Pharmacokinetic parameters (Mean ±SD) of BUP and HBUP in different CYP2B6 genotypes.

| PK parameters | CYP2B6*1/*1 (n=11) | CYP2B6*1/*6 (n=7) | CYP2B6*1/*4 (n=2) | CYP2B6*4/*6 (n=3) |
|---------------|-------------------|-------------------|-------------------|-------------------|
| **BUP**       |                   |                   |                   |                   |
| AUC_{0→∞} (h*ng/mL) | 845.17±180.44     | 888.08±202.75    | 786.32±11.83      | 836.03±91.49     |
| AUC_{0→t} (h*ng/mL) | 828.97±179.94     | 847.91±176.16    | 777.70±4.94       | 816.45±95.92     |
| C_{max} (ng/mL) | 98.92±22.62       | 96.34±27.77      | 77.50±4.10        | 90.43±8.36       |
| t_{1/2} (h) | 16.12±5.54        | 16.87±4.87       | 12.49±2.98        | 15.18±2.21       |
| t_{max} (h) | 2.91±1.41         | 3.07±1.40        | 4.50±0.71         | 4.17±0.76        |
| **HBUP**      |                   |                   |                   |                   |
| AUC_{0→∞} (h*ng/mL) | 7558.96±1400.38  | 4999.92±2177.85 | 19996.45±727.05  | 8442.65±3069.75  |
| AUC_{0→t} (h*ng/mL) | 180.82±38.68     | 110.33±41.10    | 356.50±54.45      | 201.67±76.55     |
| C_{max} (ng/mL) | 22.25±3.41        | 22.14±4.22       | 21.13±4.88        | 23.82±6.81       |
| t_{1/2} (h) | 6.50±2.40         | 5.71±1.38        | 6.00±1.41         | 6.33±3.21        |

* P<0.05 was statistically significant; PK – pharmacokinetic; a vs. CYP2B6*1/*1; b vs. CYP2B6*1/*6 and c vs. CYP2B6*1/*4.

Figure 1. Plasma concentration-time curves of BUP and HBUP after an oral dose of 150 mg BUP in Chinese participants with CYP2B6*1/*1 (n=11), CYP2B6*1/*6 (n=7), CYP2B6*4/*6 (n=3), and CYP2B6*1/*4 (n=2).
A rapid and sensitive method was applied for determination of BUP and HBUP in human plasma by HPLC-MS/MS based on previously published protocols [22,25]. The linear curves of BUP and HBUP in the plasma samples ranged from 0.500 ng/mL to 400 ng/mL and from 0.600 ng/mL to 480 ng/mL, respectively. HPLC-MS/MS is a reliable and robust method for BUP and HBUP analysis compared with UV detection. Meanwhile, the method of RFLP was employed restriction endonucleases to digest target specific DNA sequences [27,28] exhibiting high discriminatory power, low complexity, and high capacity in differentiating isolated geographical areas [29]. Mutations in the target site also tested positive in PCR-RFLP [30]. Amplification conditions were optimized through PCR, and the presence of PCR products was confirmed through RFLP. Through RFLP, we were able to distinctly distinguish the bands of GS167T and A785G, and accurately compare different genotypes. Furthermore, PCR-RFLP enabled us to verify the mutants we selected and analyze the exact relation between pharmacokinetics and genotypes.

The concentrations and metabolism of BUP and HBUP in plasma was affected by CYP2B6 genetic polymorphisms. The CYP2B6 gene is highly polymorphic [31], with 38 numerous allele variants [32]. Consistent with the results of previous study, CYP2B6*1/*1 and CYP2B6*1/*6 carriers were extensive metabolizers (EMs), and intermediate metabolizers (IMs), respectively [22]. CYP2B6*1/*4 was an ultra-rapid metabolizer (UMs) of BUP and thus extensively induced BUP hydroxylation [6]. In the present study, the CYP2B6*1/*6 allele carriers showed high BUP concentration and slow elimination, while CYP2B6*1/*4 carriers exhibited low BUP concentration and fast elimination. In addition, CYP2B6*4/*6 did not alter BUP concentration in the same manner as CYP2B6*1/*1. Overall, the pharmacogenetic data of CYP2B6 on BUP and HBUP concentrations indicated that catalytic diversities possibly existed in different CYP2B6 genotypes. The low hepatic expressions of c.516G>T and c.785A>G SNPs, and intermediate metabolizers (IMs), respectively [22], CYP2B6*1/*4 and CYP2B6*1/*6 accelerated BUP hydroxylation, resulting in lower BUP concentration and content. Despite the accelerated activation in CYP2B6*1/*4 participants, whose pharmacokinetics of HBUP maintained increasing levels, the BUP and HBUP profiles in CYP2B6*1/*4 carriers were not different from those in CYP2B6*1/*1 carriers but significantly differed from those of CYP2B6*1/*6 or CYP2B6*1/*4 carriers. Meanwhile, the AUC\(_{(0,\infty)}\), \(C_{\text{max}}\), and \(t_{\text{max}}\) of BUP in the CYP2B6*1/*6 group exceed those in the CYP2B6*1/*1 group. Concurrently, CYP2B6*1/*4 accelerated BUP hydroxylation, resulting in lower BUP concentration and content. Despite the accelerated activation in CYP2B6*1/*4 participants, whose pharmacokinetics of HBUP maintained increasing levels, the BUP and HBUP profiles in CYP2B6*1/*4 carriers were not different from those in CYP2B6*1/*1 carriers but significantly differed from those of CYP2B6*1/*6 or CYP2B6*1/*4 carriers. Meanwhile, the AUC\(_{(0,\infty)}\), \(C_{\text{max}}\), and \(t_{\text{max}}\) values were remarkably different between carriers of CYP2B6*1/*6 and CYP2B6*1/*1 or between CYP2B6*1/*4 and CYP2B6*1/*1, indicating the extensive metabolic properties in carriers with CYP2B6*4/*6 genotype.

### Conclusions

The CYP2B6 alleles influenced metabolic activity by altering the catalytic activity associated with BUP and HBUP. The metabolic mechanisms of BUP and HBUP were associated with CYP2B6 SNPs, which modify the catalytic properties of mutants versus wild type. When the BUP exposure was within the therapeutic window, the cutaneous effects were directly proportional to the BUP dose. To reach the ideal treatment effects and prevent toxicities, doses of CYP2B6*1/*4 (UMs), CYP2B6*1/*6 (IMs), and CYP2B6*4/*6 (EMs) carriers should be adjusted based on the therapeutic window.

The enzyme functions of CYP2B6 in the mediation of BUP and HBUP among healthy Chinese individuals requires further research. To date, the effects of genetic polymorphisms of CYP2B6 on the pharmacokinetics of BUP and HBUP in healthy Chinese individuals remains unreported. The CYP2B6 alleles alter the pharmacokinetic profiles of BUP and HBUP in a dose-dependent manner. Basing on the altered pharmacokinetics of distinctive genotypes, we found that adjusting BUP exposure was necessary to reach the therapeutic window or target concentrations for treatment and prevention of toxic reactions. Thus, when clinicians prescribe BUP to their patients, they should check whether the patients carry UM or EM genotypes (CYP2B6*1/*4, CYP2B6*4/*6, and CYP2B6*1/*1) and IM genotype (CYP2B6*1/*6).
Conflict of interest

None.

References:

1. Koenig HG, Cohen HJ, Blazer DG et al: A brief depression scale for use in the medically ill. Int J Psychiat Med, 1992; 22: 183–95
2. Koenig HG, Selph F, Goli V et al: Survival and health care utilization in elderly medical inpatients with major depression. J Am Geriatr Soc, 1989; 37: 599–606
3. Koenig HG, Meador KG, Cohen HJ, Blazer DG: Depression in elderly men hospitalized with medical illness. Arch Intern Med, 1988; 148: 1929–36
4. Rapp SR, Parisi SA, Walsh DA, Wallace CE: Detecting depression in elderly medical inpatients. J Consult Clin Psychol, 1988; 56: 509–13
5. Jefferson JW, Pradko JF, Muir KT: Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther, 2005; 27: 1685–95
6. Benowitz NL, Zhu AZX, Tyndale RF et al: Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics, 2013; 23: 135–41
7. Sridar C, Kenaan C, Hollenberg PF: Inhibition of bupropion metabolism by selegiline: Mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab and Dispos, 2012; 40: 2256–66
8. Daviss WB, Perel JM, Birmaher B et al: Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Adolesc Psychiatry, 2006; 45: 1503–9
9. Niogi R, Palacharla RC, Mohammed AR et al: Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem-Biol Interact. 2015; 230: 9–20
10. Zanger UM, Klein K, Saussele T et al: Polypharmacology CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics, 2007; 8: 743–59
11. Hesse LM, Venkatakrishnan K, Court MH et al: CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepresants. Drug Metab Dispos, 2002; 28: 1176–83
12. Faucette SR, Hawke RL, Lecluyse EL et al: Validation of bupropion hydroxylation on a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos, 2000; 28: 1222–30
13. Tomaz PR, Santos JR, Issa JS et al: CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Eur J Clin Pharmacol, 2015; 71: 1–7
14. Hailegeb H, Haslemo T, Uthus LH, Mollen E: Effect of CYP2B6 S6 on steady-state serum concentrations of bupropion and hydroxybupropion in psychiatric patients: A study based on therapeutic drug monitoring data. J Clin Pharmacol, 2015; 55: 589–93
15. Qin WI, Zhang W, Liu ZQ et al: Rapid clinical induction of bupropion hydroxylation by metabolize in healthy Chinese men. Brit J Clin Pharmacol, 2012; 74: 999–1004
16. Zhu AZ, Cox LS, Nollen N et al: CYP2B6 and bupropion’s smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther, 2012; 92: 771–77
17. Midha KK, Rawson MI, Mckay G, Hubbard IW: Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion. Int J Pharm Thera, 2005; 45: 244–54
18. Posner J, Bye A, Dean K et al: The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol, 1985; 29: 97–103
19. Lainesse A, Hussain S, Monif T et al: Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. Arzneimittel Forschung, 2008; 58(5): 242–47
20. Coles R, Karakash ED: Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2007; 857(1): 67–75
21. Tao WA, FCG, Coogs RK: Mass spectrometric quantitation of chiral drugs by the kinetic method. Anal Chem, 2001; 73: 1692–98
22. Parekh JM, Sutaria DK, Vaghtla RN et al: Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: Application to a bioequivalence study in healthy Indian subjects. Biomed Chromatogr, 2012; 26: 314–26
23. Denooz R, Mercereille M, Lachatré G, Charmier C: Ultra-performance liquid chromatography- tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J Anal Toxicol, 2010; 34: 280–86
24. Hiratsuka M, Hinaí Y, Konno Y et al: Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab Pharmacokinet, 2011; 26(5): 544–47
25. Borges V, Yang E, Dunn J, Henion J: High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column. J Chromatogr B Analyt Technol Biomed Life Sci, 2004; 804(2): 277–87
26. Loboz KK, Gross AS, Ray J, McLachlan AI: HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2005; 823(2): 115–21
27. Djenne B, Pavlik I, Svastova P et al: Is 900 restriction fragment length polymorphism (RFLP) analysis of mycobacterium avium subsp. paratuberculosis isolates from goats and cattle in norway. Acta Vet Scand, 2005; 46: 1–6
28. Şahin E: Evaluation of antiviral resistant hepatitis B virus subpopulations in patients with chronic hepatitis B by using terminal restriction fragment length polymorphism. Virus Disease, 2015; 26: 267–75
29. Voskrenenskaya E, Savin C, Leclercq A et al: Typing and clustering of yersinia pseudotuberculosis isolates by restriction fragment length polymorphism analysis using insertion sequences. J Clin Microbiol, 2014; 52: 1978–89
30. Owen RJ, Sharp SI, Chisholm SA, Rijpkema S: Identification of caga tyrosine phosphorylation DNA motifs in Helicobacter pylori isolates from peptic ulcer patients by novel PCR-restriction fragment length polymorphism and real-time fluorescence PCR assays. J Clin Microbiol, 2003; 41(7): 3112–18
31. Zanger UM, Klein K: Pharmacogenocetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front Genet, 2013; 4: 24
32. Karakash ED, Regina KJ, Blood J, Friedel C: Methadone pharmacogenocetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism. Anesthesiology, 2015; 123: 1142–53
33. Sumonwall U, Sinrat L, Weerawat M et al: Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected thal adults. AIDS Res Ther, 2010; 7: 8
34. Labib RM, Abdelaah MEA, Elami E et al: CYP2B6 rs2279343 is associated with improved survival of pediatric rhabdomyosarcoma treated with cyclophosphamide. PLoS One, 2016; 11: e0158890
35. Jinno H, Tanakagakawa T, Ohto A et al: Functional characterization of cytochrome P450 2B6 allele variants. Drug Metab Dispos, 2003; 31(4): 398–403
36. Xu C, Obign ET, Guo Y, Desta Z: Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: Implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos, 2014; 40: 717–25